

**Application number**

2467017

**Type(s)**

Design

**Category**

Trademark

**CIPO Status**

FORMALIZED

**TM5 status**

LIVE/APPLICATION/ Awaiting Examination



The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.

**Filed**

2026-04-02

**Current owner**

AstraZeneca UK Limited  
1 Francis Crick Avenue,  
Cambridge Biomedical  
Campus  
Cambridge, CB2 0AA  
UNITED KINGDOM

**Agent**

LEI ZHOU  
(WITMART INC)  
18 King Street East, Suite 1400  
Toronto  
ONTARIO M5C1C4

**Applicant**

Dizal Pharmaceutical Co., Ltd.  
Rm.404, 405, 416,Building C,  
Huirong Square,No.26 Hefeng  
Road,Xinwu District  
Wuxi, Jiangsu Province,  
CHINA

**Old Owner**

**Index headings**

ZEGFROVY

**Vienna information (Code & Description)**

|           |                                                                                                                    |
|-----------|--------------------------------------------------------------------------------------------------------------------|
| 26.4.4    | Other irregular parallelograms, trapezia and quadrilaterals, quadrilaterals containing one or more rounded corners |
| 26.4.9    | Several quadrilaterals juxtaposed, joined or intersecting                                                          |
| A 26.4.24 | Quadrilaterals with dark surfaces or parts of surfaces                                                             |
| 26.1.2    | Ellipses                                                                                                           |
| A 26.1.24 | Circles or ellipses with dark surfaces or parts of surfaces                                                        |

**Foreign Character Translation**

"ZEGFROVY" is a coined term and has no meaning in English or French.

**Goods (Nice class & Statement)**

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5 | (1) Anti-cancer preparations; antitumor drugs; antivirals; biological preparations made from human blood cells for cell therapy; biopharmaceuticals for the treatment of cancer; chemotherapeutics; diagnostic chemical reagents for medical purposes; drug delivery agents in the form of dissolvable tablets that provide rapid release of the active ingredients for a wide variety of pharmaceuticals; excipients for use in pharmaceuticals to treat cancer; human pharmaceuticals for treatment of cancer; injectable preparations made of solutions of hyaluronic acid for medical and pharmaceutical purposes; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for the treatment of interstitial lung disease (ILD); pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of cancer; tumor suppressing agents |
|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Recordals (known also as Footnotes)**

**CHANGE IN TITLE / CHANGEMENT EN TITRE:**

TYPE OF CHANGE / GENRE DE CHANGEMENT: Assignment / Cession

DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2026-10-13

DATE OF CHANGE / DATE DE CHANGEMENT: 2026-10-12

COMMENTS / COMMENTAIRES: FROM/DE: Dizal Pharmaceutical Co., Ltd.

TO/A: AstraZeneca UK Limited

Dizal Pharmaceutical Co., Ltd.  
Rm.404, 405, 416,Building C,  
Huirong Square,No.26 Hefeng  
Road,Xinwu District  
Wuxi, Jiangsu Province,  
CHINA

Documents

[View documents](#)

Action History

| Action                     | Action date | Due date | Comments           |
|----------------------------|-------------|----------|--------------------|
| Filed                      | 2026-04-02  |          |                    |
| Created                    | 2026-04-02  |          |                    |
| Formalized                 | 2026-04-02  |          |                    |
| Change of Title Registered | 2026-10-13  |          | Assignment/Cession |